Everforth Inc quarterly report, Q2 FY2011

Business Context and Reporting Period

Company: On Assignment, Inc. (Note: Input metadata listed "Everforth Inc," but the filing text identifies the registrant as On Assignment, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2011
Business Overview: A diversified professional staffing firm operating in four segments: Life Sciences, Healthcare, Physician, and IT and Engineering. The company provides flexible and permanent staffing solutions for specialty skills including laboratory/scientific, healthcare/nursing, physicians, and IT/engineering.

Key Financial Metrics

Metric (in thousands) Q1 2011 Q1 2010
Revenues $129,438 $96,313
Gross Profit $43,154 $30,823
Gross Margin 33.3% 32.0%
Operating Income $6,399 $992
Net Income $3,164 $(302)
Diluted EPS $0.08 $(0.01)
Cash from Operations $5,778 $6,412
Cash and Equivalents (End of Period) $15,821 $30,250
Total Debt (Current + Long-term) $78,500 $66,750
Working Capital $51,676 $50,596

Material Changes vs. Prior Period

  • Revenue Growth: Consolidated revenues increased 34.4% year-over-year, driven by strong performance in the IT and Engineering segment (+67.9%) and Life Sciences segment (+43.0%).
  • Profitability: The company returned to profitability, reporting net income of $3.2 million compared to a net loss of $0.3 million in the prior year. Operating income surged to $6.4 million from $1.0 million.
  • Segment Performance:
    • IT & Engineering: Revenue grew significantly due to a 54.8% increase in contract professionals on assignment.
    • Life Sciences: Revenue growth attributed to increased demand and the impact of recent acquisitions (Cambridge, Sharpstream, Valesta).
    • Physician: Revenue declined 12.5% due to a decrease in the number of physicians on assignment, attributed to economic conditions and reduced elective procedures.
  • Acquisition Activity: The company acquired Valesta (a clinical research staffing provider) in February 2011 for an estimated $23.6 million ($16.8 million cash + earn-outs). This contributed $2.0 million in revenue and $0.1 million in net income for the quarter.
  • Debt Structure: Total debt increased to $78.5 million. The company utilized its credit facility to fund the Valesta acquisition and refinanced existing debt.

Guidance, Outlook, and Risks

  • Outlook: Management expects demand to strengthen in the second and third quarters, consistent with historical seasonality. The strategy focuses on organic growth and strategic acquisitions.
  • Capital Expenditures: Estimated at approximately $7.4 million for 2011, largely driven by the build-out of a new corporate headquarters.
  • Liquidity: Management believes working capital ($51.7 million), the credit facility, and operating cash flows are sufficient to fund operations and debt obligations for the next 12 months.
  • Risks:
    • Uncertain economic environment impacting client demand.
    • Ability to attract and retain qualified staffing consultants.
    • Foreign currency fluctuations (operations in Europe, Canada, Australia, NZ).
    • Interest rate risk on variable rate debt (partially hedged via a $25 million interest rate swap).
  • Contingencies: The company is partially self-insured for workers' compensation and medical malpractice, with reserves of approximately $10.6 million. There are no material pending legal proceedings expected to have an adverse effect.

Investor Verification Checklist

  • Acquisition Integration: Verify the realization of synergies and revenue targets from the Valesta, Cambridge, and Sharpstream acquisitions.
  • Debt Covenants: Confirm continued compliance with leverage ratios and fixed charge coverage ratios under the senior secured credit agreement.
  • Seasonality Trends: Monitor Q2 and Q3 results to confirm the anticipated seasonal demand increase.
  • Physician Segment Recovery: Assess whether the decline in the Physician segment stabilizes as economic conditions improve.
  • Capital Expenditure Execution: Track the completion and cost efficiency of the new corporate headquarters build-out.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.